NYSE:NVRO - Nevro Stock Price, Price Target & More

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro Corp (NYSE:NVRO) released its quarterly earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The medical equipment provider had revenue of $97.96 million for the quarter, compared to analysts' expectations of $96.87 million. Nevro had a negative net margin of 11.53% and a negative return on equity of 16.32%. The firm's revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.34) earnings per share. View Nevro's Earnings History.

Nevro is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Nevro.

9 equities research analysts have issued 12-month price objectives for Nevro's shares. Their predictions range from $83.00 to $110.00. On average, they expect Nevro's stock price to reach $96.00 in the next twelve months. This suggests a possible upside of 71.4% from the stock's current price. View Analyst Ratings for Nevro.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Nevro include ICU Medical (ICUI), Hill-Rom (HRC), Globus Medical (GMED), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX) and Tandem Diabetes Care (TNDM).

News headlines about NVRO stock have been trending somewhat positive on Monday, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nevro earned a media sentiment score of 0.15 on Accern's scale. They also gave headlines about the medical equipment provider an impact score of 46.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Nevro's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.24%), Bank of Montreal Can (0.10%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Michael F Demane and Wilfred E Jaeger. View Insider Buying and Selling for Nevro.

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $56.00.

Nevro has a market capitalization of $1.73 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]